Gå offline med appen Player FM !
Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting
Manage episode 456262384 series 3389426
touchEXPERT OPINIONS for touchONCOLOGY
Listen to an oncologist, urologist and oncology nurse highlight the key data for immunotherapy in the perioperative setting for muscle-invasive bladder cancer, practical considerations for its use in clinical practice, and how possible side effects can be monitored for and managed. They also consider the role of the multidisciplinary team in implementing this treatment modality.
The experts
- Dr Laura Mertens, Netherlands Cancer Institute, Amsterdam, The Netherlands
- Prof. Thomas Powles, Barts Cancer Centre, London, UK
- Ms Lindsay Diamond, Icahn School of Medicine at Mount Sinai, New York, NY, USA
This touchPODCAST is for healthcare professionals outside of the UK only.
This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.
For further information visit our website:
www.touchONCOLOGY.com
102 episoder
Manage episode 456262384 series 3389426
touchEXPERT OPINIONS for touchONCOLOGY
Listen to an oncologist, urologist and oncology nurse highlight the key data for immunotherapy in the perioperative setting for muscle-invasive bladder cancer, practical considerations for its use in clinical practice, and how possible side effects can be monitored for and managed. They also consider the role of the multidisciplinary team in implementing this treatment modality.
The experts
- Dr Laura Mertens, Netherlands Cancer Institute, Amsterdam, The Netherlands
- Prof. Thomas Powles, Barts Cancer Centre, London, UK
- Ms Lindsay Diamond, Icahn School of Medicine at Mount Sinai, New York, NY, USA
This touchPODCAST is for healthcare professionals outside of the UK only.
This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.
For further information visit our website:
www.touchONCOLOGY.com
102 episoder
Alle episoder
×1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37
1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38
1 Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15
1 Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY 34:20
1 Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY 34:19
1 Advances in IOL technology and power calculations: Updates and innovations from 2024 13:58
1 Supporting healing in epidermolysis bullosa: Innovations and new directions for care 18:55
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14
1 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57
Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.